Agilent TechnologiesandImperial College London have signed a strategic scientific collaboration agreement that brings together Agilent’s analytical technologies with Imperial researchers
Two reports published in Biological Psychiatry demonstrate an approach to use electronic health records to more accurately investigate neuropsychiatric symptoms.
Researchers at Earlham Institute (EI) have released ‘GeneSeqToFamily’, an open-source Galaxy workflow that helps scientists to find gene families based on the ‘EnsemblCompara GeneTrees’ pipeline.
DNAnexus has announced a software solution which focuses on next-generation sequencing (NGS) driven adaptive trial design to optimise and reduce the risk of clinical trials
The Pistoia Alliance, has announced the launch of the User Experience for Life Sciences (UXLS) Toolkit - to help life science companies improve user experience in line with other global industries
This year the Paperless Lab Academy (#PLA2018) conference will move to a new location overlooking Lake Maggiore on the southern side of the Alps, near Milan, Italy. The central theme will focus on how to ‘Empower your eData Life Cycle.’
Optalysys, a start-up commercialising optical coprocessors for AI/deep learning, and genomic research institute The Earlham Institute (EI) have announced the completion of the Genetic Search System (GENESYS) project
Optibrium, a developer of software for small molecule drug discovery, today announced it has appointed Dr Scott Lyon as director of business development and relocated its Headquarters and research facilities, to Cambridge Innovation Park, Cambridge, UK
Qlucore and Nebion have started a collaboration to provide scientists with an end-to-end solution for gene expression analysis, by combining Qlucore Omics Explorer and Genevestigator into a single end to end software package
Research carried out Barcelona Supercomputing Center (BSC) which reanalysed public genetic data using innovative computational methods has enabled the identification of new genetic markers associated with an increased risk to develop Type 2 Diabetes (T2D)
Drug development is facing change – both from technological pressures, such as the use of AI and machine learning, plus new regulations which are driving sweeping changes to the way electronic records are created and stored for clinical trials.
Robert Roe speaks with laboratory informatics software providers about the future of their software and the introduction of new technologies, such as AI and deep learning
Scientists are now beginning to use new technologies such as the internet of things (IoT), artificial intelligence (AI) and machine learning (ML) in their daily workflows.
In today’s world, where drug development integrates science and technology, consumer safety is paramount in the pharmaceutical industry.
